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PMH34
CHARACTERIZATION AND ASSESSMENT OF 
DEPRESSION IN A CHRONIC NON-MALIGNANT 
PAIN POPULATION USING TWO DIFFERENT 
METHODOLOGIES IN A CLAIMS DATABASE
Mody SH1, Hsu AY2, Dodd SL1
1Janssen Pharmaceutica, Titusville, NJ, USA; 2Janssen Research 
Foundation, Titusville, NJ, USA
There are numerous methods for identifying patients
with depression from claims databases. Different indica-
tors for disease may lead to different results in both pop-
ulation and health resource utilization. OBJECTIVE: To
evaluate the economic impact of depression in a chronic
non-malignant pain (CNMP) population using two dif-
ferent indicators for depression. METHODS: The 1995–
1997 MarketScan claims database was used to identify a
CNMP cohort. Patients were labeled with CNMP if two
or more prescriptions for a long-acting opioid were given
in any one-year period. Depression was categorized in
this cohort using two different methods: ICD-9-CM diag-
nosis or antidepressant claim. Antidepressant usage (1997
numbers) was categorized as patients having a claim for
TCAs (n  157), SSRIs (n  143), other antidepressants
(n  36), combination of antidepressants (n  236), or
no claims (n  233). Resource utilization was measured
using outpatient, inpatient, and prescription costs. RE-
SULTS: For the 1997 CNMP cohort, 805 subjects were
identified. Using ICD-9-CM diagnoses (depression n 
159, non-depression n  646), demographics between
the groups were similar, with the non-depression group
represented by a higher percentage of males (46% versus
35%). Average inpatient ($19,303 versus $11,419), out-
patient ($12,665 versus $7738), prescription ($6486 ver-
sus $4548), and total ($38,454 versus $23,705) costs
were all higher for the CNMP group diagnosed with de-
pression. Similar values were also derived from the 1995
(n  154) and 1996 (n  323) cohorts. Using the second
methodology (categorizing depression by antidepressant
usage) showed that the group not prescribed antidepres-
sants had the lowest overall cost utilizing the same 1997
cohort. However, in 1995 and 1996, the group taking no
antidepressants did not have the lowest costs in either of
these years. Categorizing patients through antidepressant
usage resulted in conflicting differences between the
groups. CONCLUSION: Characterization and assess-
ment of depression using different methodologies in a
claims database led to different results in both the popu-
lation identified as well as total costs.
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ECONOMIC OUTCOMES WITH NEWER 
ANTIDEPRESSANTS FOR THE TREATMENT OF 
DEPRESSION IN A COMMERCIALLY-INSURED 
POPULATION
Mukherjee R, Lian J, Hines P, Dezii C, Chen S, Scull R, Alter C
Bristol-Myers Squibb Company, Plainsboro, NJ, USA
OBJECTIVES: To evaluate whether nefazodone HCl’s
clinical attributes translate to depression-related eco-
nomic savings during the first six months of antidepres-
sant therapy, relative to bupropion, fluoxetine, paroxet-
ine, sertraline, and venlafaxine. METHODS: We screened
the pharmacy and medical claims for all members of a
large, geographically diverse managed care organization
who were prescribed an antidepressant for the diagnosis
of a depressive disorder during the period 1/95 through
6/98. Patients had initiated new episodes of antidepres-
sant therapy and were characterized by having no preex-
isting anxiolytic or sedative/hypnotic use. The six-month
window immediately following antidepressant initiation
was screened for two primary outcomes: depression-
related pharmacy cost and depression-related medical
cost (drawn from all medical services for which a diagno-
sis of depression was recorded). Depression-related phar-
macy cost was defined as the cost incurred by the payor
for the index antidepressant, as well as the costs for any
additional medications, such as anxiolytics, sedative/hyp-
notics, and low-dose older antidepressants. RESULTS: A
total of 1,961 antidepressant users satisfied our eligibility
criteria. The rate of concomitant medication utilization
among nefazodone users within six months of antide-
pressant initiation was nearly twofold lower (11.9%)
than with the other antidepressant treatment groups
(19.7%–27.9%). After adjusting for age, gender, and
prior total 4-month medical and pharmacy utilization us-
ing a multivariate regression analysis, nefazodone emerged
as a significant predictor of 6-month depression-related
pharmacy and medical cost savings. Nefazodone was as-
sociated with a cost reduction of $129 per patient, rela-
tive to non-nefazodone treatment (P  0.05). When com-
pared with nefazodone, each antidepressant treatment
group was associated with significant incremental 6-month
depression-related cost (P  0.05 for each comparison).
CONCLUSIONS: Nefazodone’s co-prescription rate was
approximately one-half that observed for fluoxetine, par-
oxetine, sertraline, venlafaxine, and bupropion. It was a
significant predictor of 6-month depression-related cost
savings to the payer.
PMH36
CONFORMANCE WITH ANTIPSYCHOTIC 
DRUG THERAPY GUIDELINES FOR TREATING 
SCHIZOPHRENIA IN THE CALIFORNIA 
MEDICAID (MEDI-CAL) PROGRAM
Luo M, McCombs JS, Shi L, Stimmel GL
University of Southern California, Los Angeles, CA, USA
OBJECTIVE: To investigate the conformance of antipsy-
chotic drug therapy used to treat Medi-Cal patients with
schizophrenia to the Schizophrenia Patient Outcomes Re-
search Team (PORT) Treatment Recommendations and
to measure the impact of conformance on direct health
care costs. METHODS: Minimum effective doses and
completed therapy were defined based on the PORT Rec-
ommendations. We identified 2,567 patients with schizo-
